Attributes of Oct4 in stem cell biology: Perspectives on cancer stem cells of the ovary

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Samardzija, Chantel ^a,b   Quinn, Michael ^a,b   Findlay, Jock K ^a,b,c   Ahmed, Nuzhat ^a,b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cancer stem cell; Chemoresistance; Embryonic stem cells; Induced pluripotent stem cells; Metastasis; Ovarian carcinoma; Recurrence

Indexed keywords

CD133 ANTIGEN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL TRANSDIFFERENTIATION; EMBRYONIC STEM CELL; HUMAN; NONHUMAN; OVARY CARCINOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 84869206625     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-37     Document Type: Review

References (118)

1. Focus on epithelial ovarian cancer. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Cancer Cell 2004 5 19 24 S1535610804000029 [pii] 14749123 (Pubitemid 38121593)
2. Ovarian-cancer-facts.com C, Ovarian Cancer Statistics
3. Ovarian cancer pathogenesis: a model in evolution. Karst AM, Drapkin R, J Oncol 2010 932371
4. Ovarian surface epithelium: biology, endocrinology, and pathology. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, Endocr Rev 2001 22 255 288 10.1210/er.22.2.255 11294827 (Pubitemid 32458162)
5. Systemic therapy for ovarian cancer: current status and new treatments. Ozols RF, Semin Oncol 2006 33 3 11 17223444
6. Ovarian cancer development and metastasis. Lengyel E, Am J Pathol 2010 177 1053 1064 10.2353/ajpath.2010.100105 20651229
7. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. Ahmed N, Thompson EW, Quinn MA, J Cell Physiol 2007 213 581 588 10.1002/jcp.21240 17708542 (Pubitemid 350058249)
8. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Hudson LG, Zeineldin R, Stack MS, Clin Exp Metastasis 2008 25 643 655 10.1007/s10585-008-9171-5 18398687
9. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Ahmed N, Abubaker K, Findlay J, Quinn M, Curr Cancer Drug Targets 2010 10 268 278 10.2174/156800910791190175 20370691
10. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. J Cell Biochem 2011 112 2850 2864 10.1002/jcb.23199 21618587
11. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Clin Cancer Res 2012 18 869 881 10.1158/1078-0432.CCR-11-2188 22142828
12. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency. Kellner S, Kikyo N, Histol Histopathol 2010 25 405 412 20054811
13. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, et al. Cell 1998 95 379 391 10.1016/S0092- 8674(00)81769-9 9814708 (Pubitemid 28507326)
14. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Niwa H, Miyazaki J, Smith AG, Nat Genet 2000 24 372 376 10.1038/74199 10742100 (Pubitemid 30187435)
15. A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues. Ratajczak MZ, Machalinski B, Wojakowski W, Ratajczak J, Kucia M, Leukemia 2007 21 860 867 17344915 (Pubitemid 46672060)
16. Molecular characterization of isolated from murine adult tissues very small embryonic/epiblast like stem cells (VSELs). Shin DM, Liu R, Klich I, Ratajczak J, Kucia M, Ratajczak MZ, Mol Cells 2010 29 533 538 10.1007/s10059-010-0081-4 20526817
17. Putative stem cells with an embryonic character isolated from the ovarian surface epithelium of women with no naturally present follicles and oocytes. Virant-Klun I, Zech N, Rozman P, Vogler A, Cvjeticanin B, Klemenc P, et al. Differentiation 2008 76 843 856 10.1111/j.1432-0436.2008.00268.x 18452550
18. Epiblast/germ line hypothesis of cancer development revisited: lesson from the presence of Oct-4+ cells in adult tissues. Ratajczak MZ, Shin DM, Liu R, Marlicz W, Tarnowski M, Ratajczak J, et al. Stem Cell Rev 2010 6 307 316 10.1007/s12015-010-9143-4 20309650
19. Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Shin DM, Zuba-Surma EK, Wu W, Ratajczak J, Wysoczynski M, Ratajczak MZ, et al. Leukemia 2009 23 2042 2051 10.1038/leu.2009.153 19641521
20. Umbilical cord blood-derived very small embryonic like stem cells (VSELs) as a source of pluripotent stem cells for regenerative medicine. Ratajczak MZ, Suszynska M, Pedziwiatr D, Mierzejewska K, Greco NJ, Pediatr Endocrinol Rev 2012 9 639 643 22523831
21. Very small embryonic-like stem cells in cardiovascular repair. Wojakowski W, Kucia M, Zuba-Surma E, Jadczyk T, Ksiazek B, Ratajczak MZ, et al. Pharmacol Ther 2011 129 21 28 10.1016/j.pharmthera.2010.09.012 20971132
22. A novel insight into aging: are there pluripotent very small embryonic-like stem cells (VSELs) in adult tissues overtime depleted in an Igf-1-dependent manner? Ratajczak MZ, Shin DM, Ratajczak J, Kucia M, Bartke A, Aging (Albany NY) 2010 2 875 883
23. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Takahashi K, Yamanaka S, Cell 2006 126 663 676 10.1016/j.cell.2006.07.024 16904174 (Pubitemid 44233629)
24. Direct reprogramming of human neural stem cells by OCT4. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Nature 2009 461 649 643 10.1038/nature08436 19718018
25. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Nat Biotechnol 2008 26 1276 1284 10.1038/nbt.1503 18931654
26. Induced pluripotent stem cell lines derived from human somatic cells. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Science 2007 318 1917 1920 10.1126/science.1151526 18029452
27. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Moon JH, Heo JS, Kim JS, Jun EK, Lee JH, Kim A, et al. Cell Res 2011 21 1305 1315 10.1038/cr.2011.107 21709693
28. Concise review: Oct4 and more: the reprogramming expressway. Sterneckert J, Hoing S, Scholer HR, Stem Cells 2012 30 15 21 10.1002/stem.765 22009686
29. Oct-3/4: not just a gatekeeper of pluripotency for embryonic stem cell, a cell fate instructor through a gene dosage effect. Stefanovic S, Puceat M, Cell Cycle 2007 6 8 10 10.4161/cc.6.1.3633 17245123 (Pubitemid 46173872)
30. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Heng JC, Feng B, Han J, Jiang J, Kraus P, Ng JH, et al. Cell Stem Cell 2010 6 167 174 10.1016/j.stem.2009.12.009 20096661
31. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. Cell Stem Cell 2010 7 51 63 10.1016/j.stem.2010.04.014 20621050
32. Mediators of induced pluripotency and their role in cancer cells-current scientific knowledge and future perspectives. Bernhardt M, Galach M, Novak D, Utikal J, Biotechnol J 2012 7 1 12
33. Telomere and telomerase in stem cells. Hiyama E, Hiyama K, Br J Cancer 2007 96 1020 1024 10.1038/sj.bjc.6603671 17353922 (Pubitemid 46608315)
34. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, et al. Nat Biotechnol 2007 25 207 215 10.1038/nbt1285 17287758 (Pubitemid 46227120)
35. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. Nat Genet 2008 40 499 507 10.1038/ng.127 18443585 (Pubitemid 351601215)
36. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, et al. Cancer Res 2010 70 7662 7673 10.1158/0008-5472.CAN-10-1361 20841480
37. Cancer genes hypermethylated in human embryonic stem cells. Calvanese V, Horrillo A, Hmadcha A, Suarez-Alvarez B, Fernandez AF, Lara E, et al. PLoS One 2008 3 3294 10.1371/journal.pone.0003294 18820729
38. Embryonic stem cell lines derived from human blastocysts. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Science 1998 282 1145 1147 9804556 (Pubitemid 28516247)
39. Embryonic stem cell markers expression in cancers. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B, Biochem Biophys Res Commun 2009 383 157 162 10.1016/j.bbrc.2009.02.156 19268426
40. Lin28 promotes transformation and is associated with advanced human malignancies. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Nat Genet 2009 41 843 848 10.1038/ng.392 19483683
41. Oct-3/4 is a dose-dependent oncogenic fate determinant. Gidekel S, Pizov G, Bergman Y, Pikarsky E, Cancer Cell 2003 4 361 370 10.1016/S1535-6108(03) 00270-8 14667503 (Pubitemid 37491097)
42. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Hochedlinger K, Yamada Y, Beard C, Jaenisch R, Cell 2005 121 465 477 10.1016/j.cell.2005.02.018 15882627 (Pubitemid 40692305)
43. [Expression of OCT4 protein in bladder cancer and its clinicopathological implications]. Nan Fang Yi Ke Da Xue Xue Bao =. Zhao P-P, Liu C-X, Xu K, Zheng S-B, Li H-L, Xu Y-W, et al. Journal Of Southern Medical University 2012 32 643 646 22588915
44. Prognostic significance of OCT4 expression in adenocarcinoma of the lung. Zhang X, Han B, Huang J, Zheng B, Geng Q, Aziz F, et al. Jpn J Clin Oncol 2010 40 961 966 10.1093/jjco/hyq066 20462980
45. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Huang P, Chen J, Wang L, Na Y, Kaku H, Ueki H, et al. Medical Oncology (Northwood, London, England) 2012 29 829 834 10.1007/s12032-011-9962-4
46. Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours. Rijlaarsdam MA, van Herk HADM, Gillis AJM, Stoop H, Jenster G, Martens J, et al. British Journal Of Cancer 2012 105 854 863
47. Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. He W, Li K, Wang F, Qin Y-R, Fan Q-X, World J Gastroentero 2012 18 712 719 10.3748/wjg.v18.i7.712
48. Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells. Chen Z, Wang T, Cai L, Su C, Zhong B, Lei Y, et al. J Exp Clin Canc Res 2012 31 10 10 10.1186/1756-9966-31-10
49. OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Karoubi G, Gugger M, Schmid R, Dutly A, Interactive Cardiovascular And Thoracic Surgery 2009 8 393 397 10.1510/icvts.2008.193995 19126554
50. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, et al. Breast Cancer Res 2011 13 94 10.1186/bcr3019 21952072
51. OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Kim RJ, Nam JS, Lab Anim Res 2011 27 147 152 10.5625/lar.2011.27.2.147 21826175
52. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. Chen Y-C, Hsu H-S, Chen Y-W, Tsai T-H, How C-K, Wang C-Y, et al. PLoS One 2008 3 2637 e2637 10.1371/journal.pone.0002637 18612434
53. The basics of epithelial-mesenchymal transition. Kalluri R, Weinberg RA, J Clin Invest 2009 119 1420 1428 10.1172/JCI39104 19487818
54. The role of epithelial-mesenchymal transition in cancer pathology. Guarino M, Rubino B, Ballabio G, Pathology 2007 39 305 318 10.1080/ 00313020701329914 17558857 (Pubitemid 46897605)
55. The epithelial-mesenchymal transition generates cells with properties of stem cells. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. Cell 2008 133 704 715 10.1016/j.cell.2008.03.027 18485877 (Pubitemid 351636299)
56. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C, Oncogene 2011 36 4609 21
57. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. PLoS One 2010 5 12445 10.1371/journal.pone.0012445 20805998
58. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Chiou S-H, Wang M-L, Chou Y-T, Chen C-J, Hong C-F, Hsieh W-J, et al. Cancer Res 2012 70 10433 10444
59. Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Hu J, Qin K, Zhang Y, Gong J, Li N, Lv D, et al. Biochem Biophys Res Commun 2011 411 786 791 10.1016/j.bbrc.2011.07.025 21798248
60. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, et al. Genes & Cancer 2011 1 908 916 23275942
61. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Hepatology (Baltimore, Md) 2010 52 528 539 10.1002/hep.23692
62. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY, J Oral Pathol Med 2011 40 621 628 10.1111/j.1600-0714.2011.01015.x 21342274
63. Ovarian pluripotent/multipotent stem cells and in vitro oogenesis in mammals. Virant-Klun I, Stimpfel M, Skutella T, Histol Histopathol 2011 26 1071 1082 21692039
64. Detection, characterization, and spontaneous differentiation in vitro of very small embryonic-like putative stem cells in adult mammalian ovary. Parte S, Bhartiya D, Telang J, Daithankar V, Salvi V, Zaveri K, et al. Stem Cells Dev 2011 20 1451 1464 10.1089/scd.2010.0461 21291304
65. Stem cell interaction with somatic niche may hold the key to fertility restoration in cancer patients. Bhartiya D, Sriraman K, Parte S, Obstet Gynecol Int 2012 921082
66. Parthenogenetic embryo-like structures in the human ovarian surface epithelium cell culture in postmenopausal women with no naturally present follicles and oocytes. Virant-Klun I, Rozman P, Cvjeticanin B, Vrtacnik-Bokal E, Novakovic S, Rulicke T, et al. Stem Cells Dev 2009 18 137 149 10.1089/scd.2007.0238 18605894
67. Ovarian surface epithelium in patients with severe ovarian infertility: a potential source of cells expressing markers of pluripotent/multipotent stem cells. Virant-Klun I, Skutella T, Stimpfel M, Sinkovec J, J Biomed Biotechnol 2011 381928
68. OCT4: a novel biomarker for dysgerminoma of the ovary. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW, Am J Surg Pathol 2004 28 1341 1346 10.1097/01.pas.0000135528.03942.1f 15371950 (Pubitemid 39336373)
69. Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. Abiko K, Mandai M, Hamanishi J, Matsumura N, Baba T, Horiuchi A, et al. Am J Surg Pathol 2010 34 1842 1848 10.1097/PAS.0b013e3181fcd707 21107090
70. Expression of octamer-4 in serous and mucinous ovarian carcinoma. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ, J Clin Pathol 2010 63 879 883 10.1136/jcp.2009.073593 20876318
71. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. PLoS Med 2008 5 232 10.1371/journal.pmed.0050232 19053170
72. Serous papillary adenocarcinoma possibly related to the presence of primitive oocyte-like cells in the adult ovarian surface epithelium: a case report. Virant-Klun I, Skutella T, Cvjeticanin B, Stimpfel M, Sinkovec J, J Ovarian Res 2011 4 13 10.1186/1757-2215-4-13 21827672
73. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Bapat SA, Mali AM, Koppikar CB, Kurrey NK, Cancer Res 2005 65 3025 3029 15833827 (Pubitemid 40524578)
74. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Hu L, McArthur C, Jaffe RB, Br J Cancer 2010 102 1276 1283 10.1038/sj.bjc.6605626 20354527
75. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ, PLoS One 2012 7 29079 10.1371/journal.pone.0029079 22272227
76. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Mol Cancer Ther 2011 10 325 335 10.1158/1535-7163.MCT-10-0788 21216927
77. Clinical significance of side population in ovarian cancer cells. Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K, Kiguchi K, et al. Hum Cell 2011 24 9 12 10.1007/s13577-010-0002-z 21547690
78. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Cell Cycle 2009 8 158 166 10.4161/cc.8.1.7533 19158483
79. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Oncogene 2009 28 209 218 10.1038/onc.2008.374 18836486
80. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH, Oncogene 2010 29 2672 2680 10.1038/onc.2010.35 20190812
81. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, et al. Am J Pathol 2012 180 1159 1169 10.1016/j.ajpath.2011.11.015 22222226
82. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Peng S, Maihle NJ, Huang Y, Oncogene 2010 29 2153 2159 10.1038/onc.2009.500 20101213
83. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. PLoS One 2012 7 46858 10.1371/journal.pone.0046858 23056490
84. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. Cell 2003 113 631 642 10.1016/S0092-8674(03)00393-3 12787504 (Pubitemid 36694188)
85. A novel NK-type homeobox gene, ENK (early embryo specific NK), preferentially expressed in embryonic stem cells. Wang SH, Tsai MS, Chiang MF, Li H, Gene Expr Patterns 2003 3 99 103 10.1016/S1567-133X(03)00005-X 12609610 (Pubitemid 36358184)
86. Multipotent cell lineages in early mouse development depend on SOX2 function. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R, Genes Dev 2003 17 126 140 10.1101/gad.224503 12514105 (Pubitemid 36062514)
87. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY, et al. Nat Cell Biol 2008 10 731 739 10.1038/ncb1736 18454139 (Pubitemid 351772939)
88. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. Nat Genet 2006 38 431 440 10.1038/ng1760 16518401
89. Transcriptional regulation of nanog by OCT4 and SOX2. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. J Biol Chem 2005 280 24731 24737 10.1074/jbc.M502573200 15860457 (Pubitemid 40934562)
90. Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, Bolli R, J Mol Cell Cardiol 2008 44 865 873 10.1016/j.yjmcc.2008.02.279 18430437
91. Stem cells, including a population of very small embryonic-like stem cells, are mobilized into peripheral blood in patients after skin burn injury. Drukala J, Paczkowska E, Kucia M, Mlynska E, Krajewski A, Machalinski B, et al. Stem Cell Rev 2012 8 184 194 10.1007/s12015-011-9272-4 21573962
92. Coexpression of stemness factors oct4 and nanog predict liver resection. Yin X, Li YW, Zhang BH, Ren ZG, Qiu SJ, Yi Y, et al. Ann Surg Oncol 2012 19 2877 2887 10.1245/s10434-012-2314-6 22461131
93. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Wen J, Park JY, Park KH, Chung HW, Bang S, Park SW, et al. Pancreas 2010 39 622 626 10.1097/MPA.0b013e3181c75f5e 20173672
94. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H, Pathobiology 2010 77 283 288 10.1159/000320866 21266826
95. POU domain family values: flexibility, partnerships, and developmental codes. Ryan AK, Rosenfeld MG, Genes Dev 1997 11 1207 1225 10.1101/gad.11.10.1207 9171367 (Pubitemid 27235355)
96. Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Wang X, Dai J, Stem Cells 2010 28 885 893 20333750
97. Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Liedtke S, Stephan M, Kogler G, Biol Chem 2008 389 845 850 18627312
98. The human OCT-4 isoforms differ in their ability to confer self-renewal. Lee J, Kim HK, Rho J-Y, Han Y-M, Kim J, J Biol Chem 2006 281 33554 33565 10.1074/jbc.M603937200 16951404 (Pubitemid 46036736)
99. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Bilandzic M, Farnworth PG, Harrison C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK, Stenvers KL, Mol Endocrinol 2009 23 539 548 10.1210/me.2008-0300 19164448
100. Analysis of Oct4-dependent transcriptional networks regulating self-renewal and pluripotency in human embryonic stem cells. Babaie Y, Herwig R, Greber B, Brink TC, Wruck W, Groth D, et al. Stem Cells 2007 25 500 510 10.1634/stemcells.2006-0426 17068183 (Pubitemid 46232806)
101. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Xia H, Hui KM, Cancer Gene Ther 2012 19 723 730 10.1038/cgt.2012.58 22975591
102. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R, Nat Genet 2008 40 1478 1483 10.1038/ng.250 18978791
103. MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. Liao B, Bao X, Liu L, Feng S, Zovoilis A, Liu W, et al. J Biol Chem 2011 286 17359 17364 10.1074/jbc.C111.235960 21454525
104. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Ma L, Lai D, Liu T, Cheng W, Guo L, Acta Biochimica Et Biophysica Sinica 2011 42 593 602
105. The role of let-7 in cell differentiation and cancer. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME, Endocr Relat Cancer 2010 17 19 36 10.1677/ERC-09-0184 19779035
106. Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells? Gunaratne PH, Curr Stem Cell Res Ther 2009 4 168 177 10.2174/157488809789057400 19492978
107. miR-125b promotes early germ layer specification through Lin28/let-7d and preferential differentiation of mesoderm in human embryonic stem cells. Wong SS, Ritner C, Ramachandran S, Aurigui J, Pitt C, Chandra P, et al. PLoS One 2012 7 36121 10.1371/journal.pone.0036121
108. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. Zhong X, Li N, Liang S, Huang Q, Coukos G, Zhang L, J Biol Chem 2010 285 41961 41971 10.1074/jbc.M110.169607 20947512
109. MicroRNAs in ovarian cancer biology and therapy resistance. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA, Int J Biochem Cell Biol 2010 42 1282 1290 10.1016/j.biocel.2010.01.014 20083225
110. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al. PLoS One 2011 6 18064 10.1371/journal.pone.0018064 21533284
111. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et al. Cancer Res 2008 68 10307 10314 10.1158/0008-5472.CAN-08-1954 19074899
112. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, et al. Int J Cancer 2012 130 1787 1797 10.1002/ijc.26190 21618519
113. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Proc Natl Acad Sci U S A 2008 105 3903 3908 10.1073/pnas.0712321105 18308936 (Pubitemid 351723497)
114. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, et al. Nat Cell Biol 2011 13 215 222 10.1038/ncb2164 21278734
115. Direct reprogramming of mouse fibroblasts to neural progenitors. Kim J, Efe JA, Zhu S, Talantova M, Yuan X, Wang S, et al. Proc Natl Acad Sci U S A 2011 108 7838 7843 10.1073/pnas.1103113108 21521790
116. Specific unsaturated fatty acids enforce the transdifferentiation of human cancer cells toward adipocyte-like cells. Ruiz-Vela A, Aguilar-Gallardo C, Martinez-Arroyo AM, Soriano-Navarro M, Ruiz V, Simon C, Stem Cell Rev 2011 7 898 909 10.1007/s12015-011-9253-7 21499706
117. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, et al. Br J Cancer 2005 92 113 119 10.1038/sj.bjc.6602244 15583697 (Pubitemid 40188443)
118. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, et al. Neoplasia 2006 8 851 861 10.1593/neo.06433 17032502 (Pubitemid 44564841)